Adolor (ADLR) Acquires Rights to Clinical-Stage Product Candidate from Eli Lilly and Company (LLY)
Down)
Adolor Corporation (Nasdaq: ADLR) announced that it has acquired from Eli Lilly and Company (NYSE: LLY) the exclusive worldwide rights to OpRA III, a clinical-stage product candidate.
OpRA III is a potent opioid receptor antagonist, with potential use in multiple therapeutic indications. Adolor intends to initially develop OpRA III to treat opioid bowel dysfunction (OBD) and will initiate clinical trials of this compound for this indication in early 2010. This compound will be developed in parallel with ADL7445 as part of the Company's OBD Program. Moving forward, OpRA III will be identified as ADL5945.
OpRA III is a potent opioid receptor antagonist, with potential use in multiple therapeutic indications. Adolor intends to initially develop OpRA III to treat opioid bowel dysfunction (OBD) and will initiate clinical trials of this compound for this indication in early 2010. This compound will be developed in parallel with ADL7445 as part of the Company's OBD Program. Moving forward, OpRA III will be identified as ADL5945.
You May Also Be Interested In
- Boehringer Ingelheim, Lilly (LLY) Say Linagliptin Showed Significant Improvement in HbA1c in Phase 3
- New Phase 3 data for Tradjenta® (linagliptin) tablets in black or African American patients with type 2 diabetes showed significant improvement in blood sugar
- Cytokinetics (CYTK) Opens Second Cohort for ATOMIC-AHF Phase IIb
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
